We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NIH Launches Trial of Rigel’s Fostamatinib for COVID-19 Patients
NIH Launches Trial of Rigel’s Fostamatinib for COVID-19 Patients
The National Institutes of Health (NIH) has launched a phase 2 clinical trial of Rigel Pharmaceuticals’ fostamatinib for the treatment of hospitalized COVID-19 patients.